• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Bisphosphonates/Related Products
You are here: Product Lines > Bone Metabolism > Bisphosphonates/Related Products
Toolbar - View Selection
 
Items 1 of 1
ALX-430-153 Revised 25-Mar-08
Zoledronic acid
Add to Clipboard
SYNONYMS 1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid
CGP 42446
PRODUCT LINE Bone Metabolism
PRODUCT CATEGORY Bisphosphonates/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-430-153-M025   25 mg 80.00 USD Add To Cart
ALX-430-153-M100   100 mg 240.00 USD Add To Cart
ALX-430-153-G001   1 g 550.00 USD Add To Cart
Product Specification
FORMULA: C5H10N2O7P2 . H2O
MW: 272.1 . 18.0
CAS NUMBER: 118072-93-8; 165800-06-6
MERCK INDEX: 14: 10187
SOURCE/HOST: Synthetic.
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Inhibitor of osteoclastic bone resorption. Prevents osteoporosis and skeletal fractures, particularly in patients with multiple myeloma or prostate cancer. Also used to treat hypercalcemia.
Product Specific Literature References
Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound: J.R. Green, et al.; J. Bone Miner. Res. 9, 745 (1994) Abstract
An enzyme inhibition assay for the quantitative determination of the new bisphosphonate zoledronate in plasma: F. Risser, et al.; J. Pharm. Biomed. Anal. 15, 1877 (1997) Abstract
Clinical research update: zoledronate: J.J. Body; Cancer 80, 1699 (1997) Abstract; Full Text
Intravenous zoledronic acid in postmenopausal women with low bone mineral density: I.R. Reid, et al.; New Engl. J. Med. 346, 653 (2002) Abstract
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma: F. Saad, et al.; J. Natl. Cancer Inst. 94, 1458 (2002) Abstract
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis: J.J. Body; Expert Opin. Pharmacother. 4, 567 (2003) Abstract
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis: D.M. Black, et al.; New Engl. J. Med. 356, 1809 (2007) Abstract
Further Categories Containing This Product:
Antitumor Reagents Other Products
 
 
© 2008 ALEXIS Corporation, Privacy Policy, Disclaimer, Feedbackanother CS2 website

Catalogs / Brochures

E-Newsletter

 

Shopping Cart [0]

 

Distributors

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.